Cullinan Therapeutics, Inc. · NASDAQ:CGEM
Cullinan Therapeutics — Cullinan Oncology — Technical Presentation (June 2021)
17 slides from Cullinan Therapeutics's technical presentation, Jun 4, 2021
Slide 1: Cullinan Pearl 2021 ASCO Update on CLN-081
Exhibit 99.2 Cullinan Pearl 2021 ASCO Update on CLN-081 June 4, 2021Exhibit 99.2 Cullinan Pearl 2021 ASCO Update on CLN-081 June 4, 2021
Slide 2: Important Notice and Disclaimers
Important Notice and Disclaimers This presentation contains forward-looking statements of Cullinan Oncology, Inc. (“Cullinan,” “we” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or impli
Slide 3: Executive Hosts of Today's Webinar
Executive Hosts of Today’s Webinar Owen Hughes Jeff Trigilio Chief Executive Officer Chief Financial Officer Jon Wigginton, MD Leigh Zawel, PhD Senior Adviser & Chief Scientific Officer, Chairman of SAB Small Molecules 3Executive Hosts of Today’s Webinar Owen Hughes Jeff Trigilio Chief Executive Off
Slide 4: Cullinan Pearl
cullnan PEARL
Slide 5: Cullinan Pearl (CLN-081) Selective EGFR inhibitor targeting Exon 20 insertion mutant NSCLC
Cullinan Pearl (CLN-081) Selective EGFR inhibitor targeting Exon 20 insertion mutant NSCLC Hypothesis Design § EGFR is a therapeutically validated oncogenic driver in NSCLC§ Unique scaffold (pyrrolopyrimidine) relative to all other TKIs targeting Exon 20 NSCLC § CLN‐081 is highly selective for exon
Slide 6: Cullinan Pearl Enrollment Progress
As of April 1, 2021 Cullinan Pearl Enrollment Progress Patient Enrollment Dose (BID) Accelerated Titration Rolling 6 Phase 1 Expansion Phase 2a Expansion N = 2 30 mg N = 6 45 mg N = 1 N = 1 N = 7 65 mg N = 6 100 mg N = 1 N = 6 N = 6 N = up to 23 Expansion under N = 7 150 mg consideration Geographic
Slide 7: Cullinan Pearl Baseline Demographics
As of April 1, 2021 Cullinan Pearl Baseline Demographics Select Baseline Characteristics 1 Characteristic All patients (n=44 ) Median age (range) 64 (44-82) • Heavily pretreated Number of prior systemic anticancer regimens patient population 1 (%) 12 (27%) • Greater than 70% 2 (%) 17 (39%) of patien
Slide 8: Preliminary Safety Overview
As of April 1, 2021 Preliminary Safety Overview Dose (BID) 30 mg 45 mg 65 mg 100 mg 150 mg Safety Population (n) 8 1 14 15 7 DLTs -- -- -- -- 1 Grade 1 TRAEs of interest Skin Rash 6 -- 754 Diarrhea 2 -- 1 3 1 Elevated ALT / AST 1 -- 2 2 2 Anemia -- -- 1 2 -- Grade 2 TRAEs of interest Skin Rash -- --
Slide 9: Preliminary CLN-081 Pharmacokinetics
As of April 1, 2021 Preliminary CLN-081 Pharmacokinetics Average Unbound Plasma Concentration over Time • CLN-081 well 1000 behaved to date GI -WT EGFR • Sustained Coverage 50 Over 8h Period 100 • Unbound plasma GI -Ex20insASV 50 GI -Ex20insSVD 50 concentrations are greater than GI50 10 values for E
Slide 10: Activity Across Dose Levels & Insertion Mutations
As of April 1, 2021 Activity Across Dose Levels & Insertion Mutations Treatment Duration (Months) Variant 012 345 678 9 10 11 12 13 D770_SVD 30 M, P D770_SVD 30 V769_ASV 30 M, P H773>LM 30 D770_SVD 30 V774_HV 30 V769_ASV 30 H773_NPH 30 D770_KH 45 P D770>GY 65 M D770_GNPH 65 V774_HV 65 H773_NPH 65 Pe
Slide 11: CLN-081 Acts Rapidly: 76% Of Patients With Tumor Regression At First Scan
As of April 1, 2021 CLN-081 Acts Rapidly: 76% Of Patients With Tumor Regression At First Post-Baseline Scan Change from baseline (sum of target lesions) First on-treatment scan Days 11 % change from baseline (sum of target lesions)As of April 1, 2021 CLN-081 Acts Rapidly: 76% Of Patients With Tumor
Slide 12: Percent Change from Baseline Waterfall Plot
As of April 1, 2021 Percent Change from Baseline Waterfall Plot: % Δ from Baseline in Dimensions of Target Lesions 100% 98% of Patients Achieved Either Partial 80% E Response or Stable Disease 60% 40% 20% E E E 0% E -20% E E E E -40% E E E E -60% E E -80% EEE -100% Patient dose (mg, BID) Progressive
Slide 13: Response Characteristics by Dose
As of April 1, 2021 Response Characteristics by Dose Best Response n, (%) 30 mg (n=8) 45 mg (n=1) 65 mg (n=14) 100 mg (n=13) 150 mg (n=6) Total (n=42) PR 3 (38) 0 7 (50) 7 (54) 4 (67) 21 (50) SD 5 (62) 1 (100) 6 (43) 6 (46) 2 (33) 20 (48) PD 0 0 1 (7) 0 0 1 (2) Confirmed Response 3 (38) 0 2 (14) 6 (
Slide 14: CLN-081 Selectivity Index Supports Utility In Traditional Sensitizing Mutations
CLN-081 Selectivity Index Supports Utility In Traditional Sensitizing Mutations Selectivity Index (IC ratio) 50 • CLN-081 activity evaluated in Ba/F3 cell- High Selectivity lines expressing EGFR mutations • Selectivity index is calculated as ratio of IC values for 50 WT vs indicated EGFR mutation •
Slide 15: Cullinan Pearl Life Cycle Management
Cullinan Pearl Life Cycle Management Beyond Exon 20 Beyond Exon 20 Combo NSCLC Combo 1L/2L Combination NSCLC Mono 1L strategies to address SNSCC, Atypical opportunities Exon 20 EGFR mutations, beyond Exon 20; met certain Tagrisso Goal is to 2L amplification, C797, Exon 20 failures enhance post Tagri
Slide 16: Conclusions To Date
Conclusions To Date B 1 2 3 OPTIONS Efficacy Safety Next Steps 16Conclusions To Date B 1 2 3 OPTIONS Efficacy Safety Next Steps 16
Slide 17: Q&A
Owen Hughes Jeff Trigilio Chief Executive Officer Chief Financial Officer Q&A Jon Wigginton, MD Leigh Zawel, PhD Senior Adviser & Chief Scientific Officer, Chairman of SAB Small MoleculesOwen Hughes Jeff Trigilio Chief Executive Officer Chief Financial Officer Q&A Jon Wigginton, MD Leigh Zawel, PhD
Cullinan Oncology — Technical Presentation (June 2021) on 6ix